Published May 29, 2023
Cellevate strengthens its Scientific Advisory Board with appointment of Dr. Yvonne Genzel, a leading expert in vaccine production using cell culture-based virus processes
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, today announces that PD Dr. Yvonne Genzel, has been appointed to the company’s Scientific Advisory Board. Dr. Genzel is since 2001 member of the Bioprocess Engineering group at the Max-Planck-Institute for Dynamics of…
Published May 4, 2023
Cellevate appoints Dr. Thierry Ziegler, a leading expert in biopharmaceutical development, to the Scientific Advisory Board
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, today announces that Dr. Thierry Ziegler, has been appointed to the company’s Scientific Advisory Board. Dr. Ziegler has more than 25 years of experience and expertise in biopharmaceutical development and production with the…
Published May 3, 2023
AdBIOPRO, Competence Centre for Advanced BioProduction secures 112 mkr funding
LUND, Sweden – As Cellevate published in the news on March 27, 2023, the company is one of the technology providers in the AdBIOPRO consortium with supplying nanofiber-based technology for Upstream AAV (adeno-associated virus), lentivirus and cell therapy bioproduction. The AdBIOBRO consortium today released the news about securing 112 mkr funding, which will enable AdBIOPRO…
Published April 26, 2023
Positive feasibility results for AAV vector transfection and production using Cellevat3d™ microcarriers
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, announces positive feasibility results in a collaborative study performed by RISE Research Institutes of Sweden. In this Vinnova-funded project, the results showed that Cellevat3d™ microcarriers are highly effective in promoting the growth of…
Published March 29, 2023
Cellevate expands the collaboration with the University of Dundee, UK, to optimize the use of the Cellevat3d™ microcarriers in AAV based production for cell and gene therapy
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, has expanded the collaboration with the University of Dundee in the UK to perform cell culture experiments as one of the partners engaged in the validation program of the Cellevat3d™ microcarriers in cell…
Published March 27, 2023
Cellevate supplies nanofiber-based technology for Upstream AAV, lentivirus and cell therapy bioproduction, as part of AdBIOPRO
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, announces that AdBIOPRO consortium, the Competence Center for Advanced BioProduction, at Royal Institute of Technology, Stockholm, Sweden, has had its official start on March 22, 2023. This program consists of 24 members of…
Published December 20, 2022
Cellevate awarded Vinnova/STUNS Life Science grant to run Cellevat3d™ microcarriers scale-up validation for AAV production at Testa Center
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, today announces that the company has been awarded a grant of 800.000 SEK from Vinnova/STUNS Life Science to run a validation study program for its novel Cellevat3d™ nanofiber based microcarriers at Testa Center…
Published December 1, 2022
Cellevate, Karolinska Institutet and Karolinska University Hospital to collaborate in Vinnova financed project to develop more effective production of stem cell therapies
LUND, Sweden – Cellevate, Karolinska Institutet and Karolinska University Hospital were awarded a grant of 5.25 MSEK in February 2022 from the Swedish Governmental Agency for Innovation Systems (Vinnova) for a collaboration project dedicated to the development of new technologies and techniques for cheaper more effective production of extracellular vesicles (EV) from hematopoietic & mesenchymal stem cells….
Published November 22, 2022
Leading expert in continuous bioprocess for biologics production, Associate Professor, Dr. Véronique Chotteau appointed to Cellevate’s Scientific Advisory Board
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, today announces that Associate Professor, Dr. Véronique Chotteau, has been appointed to the company’s Scientific Advisory Board. Dr. Chotteau is the Principal Investigator of the Cell Technology group at KTH (The Royal Institute…
Published November 9, 2022
Cellevate starts using SmiLe’s newly upgraded laboratories equipped for gene therapy applications
LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, has started performing the cell culture experiments for the validation of the Cellevat3d™ microcarriers in the modern laboratories provided by SmiLe Incubator, located at Medicon Village in Lund. “As SmiLe alumni members, we…
